Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 19, 2021

Role of Telemedicine in Bipolar Disorder

Author(s)Michael E. Thase, MD, Gustavo Alva, MD, DFAPA, Theresa Cerulli, MD

Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.

Episodes in this series

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 3 Clinical Impressions From Patient Case #1

EP. 3 Clinical Impressions From Patient Case #1

EP. 4 Diagnosis of Bipolar Disorder

EP. 4 Diagnosis of Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 8 Role of Telemedicine in Bipolar Disorder

EP. 8 Role of Telemedicine in Bipolar Disorder

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related to this article

bipolar

September 21st, 2026

Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.

Trending on Psychiatric Times

Interventional Options for TRD: ECT, TMS, and Esketamine

Defining Treatment-Resistant Depression In Adults